XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Restatement Of Condensed Consolidated Financial Statements (Tables)
6 Months Ended
Jun. 30, 2020
Accounting Changes and Error Corrections [Abstract]  
Schedule of Restatement of Unaudited Consolidated Financial Statements

Condensed Consolidated Balance Sheet

 

    June 30, 2020  
    As Previously Reported     Adjustments     As Restated  
                   
Assets                        
Current assets                        
Cash and cash equivalents   $ 18,550,437     $ -     $ 18,550,437  
Accounts receivable, net     5,349,876       -       5,349,876  
Inventory     10,110,786       -       10,110,786  
Prepaid expenses     521,180       2,369,369       2,890,549  
Total current assets     34,532,279       2,369,369       36,901,648  
Property and equipment, net     473,376       -       473,376  
Investment in joint venture     1,416,480       -       1,416,480  
Total assets   $ 36,422,135     $ 2,369,369     $ 38,791,504  
Liabilities and stockholders’ equity                        
Current liabilities                        
Accounts payable   $ 1,127,709     $ -     $ 1,127,709  
Accrued expenses     691,385       -       691,385  
Accrued expenses (related party)     120,000       -       120,000  
Deferred revenue     1,045,548       -       1,045,548  
Total current liabilities     2,984,642       -       2,984,642  
Accrued expenses-long-term (related party)     80,000       -       80,000  
Total liabilities     3,064,642       -       3,064,642  
Commitments and contingencies (Note 1)                        
Stockholders’ equity                        
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 and 25,600 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively     -       -       -  
Common Stock, $0.001 par value; 100,000,000 shares authorized; 27,991,042 and 17,342,922 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively     27,991       -       27,991  
Additional paid-in capital     46,726,869       -       46,726,869  
Accumulated deficit     (13,397,367 )     2,369,369       (11,027,998 )
Total stockholders’ equity     33,357,493       2,369,369       35,726,862  
Total liabilities and stockholders’ equity   $ 36,422,135     $ 2,369,369     $ 38,791,504  

  

Condensed Consolidated Statement of Operations

 

    Three Months Ended June 30, 2020  
    As Previously Reported     Adjustments     As Restated  
                   
Net revenue   $ 24,040,274     $ -     $ 24,040,274  
Cost of revenue     8,344,674       (2,369,369 )     5,975,305  
Gross profit     15,695,600       2,369,369       18,064,969  
Operating expenses                        
Sales and marketing     390,191       -       390,191  
Administrative and general     2,191,034       -       2,191,034  
Research and development     750,249       -       750,249  
Depreciation and amortization     25,218       -       25,218  
Total operating expenses     3,356,692       -       3,356,692  
Income from operations     12,338,908       2,369,369       14,708,277  
Other income                        
Interest income     38,173       -       38,173  
Interest expense     -       -       -  
Gain on disposition of assets     -       -       -  
Gain (loss) on equity method investment in joint venture     258,559       -       258,559  
Total other income     296,732       -       296,732  
Income before income taxes     12,635,640       2,369,369       15,005,009  
Provision for income taxes     -       -       -  
Net income   $ 12,635,640     $ 2,369,369     $ 15,005,009  
Net income per common share:                        
Basic   $ 0.46     $ 0.08     $ 0.54  
Diluted   $ 0.43     $ 0.08     $ 0.51  
Weighted average shares outstanding:                        
Basic     27,582,229       27,582,229       27,582,229  
Diluted     29,152,222       29,152,222       29,152,222  

  

Condensed Consolidated Statement of Operations

 

    Six Months Ended June 30, 2020  
    As Previously Reported     Adjustments     As Restated  
                   
Net revenue   $ 25,588,802     $ -     $ 25,588,802  
Cost of revenue     8,826,414       (2,369,369 )     6,457,045  
Gross profit     16,762,388       2,369,369       19,131,757  
Operating expenses                        
Sales and marketing     658,674       -       658,674  
Administrative and general     3,650,518       -       3,650,518  
Research and development     1,150,271       -       1,150,271  
Depreciation and amortization     45,966       -       45,966  
Total operating expenses     5,505,429       -       5,505,429  
Income (loss) from operations     11,256,959       2,369,369       13,626,328  
Other income                        
Interest income     45,748       -       45,748  
Interest expense     -       -       -  
Gain on disposition of assets     -       -       -  
Gain (loss) on equity method investment in joint venture     267,740       -       267,740  
Total other income     313,488       -       313,488  
Income before income taxes     11,570,447       2,369,369       13,939,816  
Provision for income taxes     -       -       -  
Net income   $ 11,570,447     $ 2,369,369     $ 13,939,816  
Net income per common share:                        
Basic   $ 0.42     $ 0.08     $ 0.50  
Diluted   $ 0.40     $ 0.08     $ 0.48  
Weighted average shares outstanding:                        
Basic     27,605,137       27,605,137       27,605,137  
Diluted     29,094,475       29,094,475       29,094,475  

 

Condensed Consolidated Statement of Cash Flows

 

    Six Months Ended June 30, 2020  
    As Previously Reported     Adjustments     As Restated  
Cash flows from operating activities                        
Net income   $ 11,570,447     $ 2,369,369     $ 13,939,816  
Adjustments to reconcile net income (loss) to cash used in operating activities:                        
Depreciation and amortization     45,966       -       45,966  
Stock-based compensation expense     1,124,242       -       1,124,242  
Accretion of notes payable discount     -       -       -  
Gain on disposition of assets     -       -       -  
Loss (gain) from equity method investment     (267,740 )     -       (267,740 )
Changes in assets and liabilities:                        
Accounts and other receivable     (5,218,494 )     -       (5,218,494 )
Prepaid and other assets     (158,614 )     (2,369,369 )     (2,527,983 )
Inventory     (10,030,838 )     -       (10,030,838 )
Deffered revenue     1,044,225       -       1,044,225  
Accounts payable and accrued expenses     1,542,347       -       1,542,347  
Net cash used in operating activities     (348,459 )     -       (348,459 )
Cash flows from investing activities                        
Purchase of property and equipment     (205,290 )     -       (205,290 )
Investment in joint venture     (714,500 )     -       (714,500 )
Net cash used in investing activities     (919,790 )     -       (919,790 )
Cash flows from financing activities                        
Proceeds from sale of common stock     19,470,005       -       19,470,005  
Proceeds from sale of preferred stock     -       -       -  
Proceeds from exercise of options and warrants     913,465       -       913,465  
Payment of offering costs     (1,457,922 )     -       (1,457,922 )
Net cash provided by financing activities     18,925,548       -       18,925,548  
Net increase in cash and cash equivalents     17,657,299       -       17,657,299  
Cash and cash equivalents at beginning of period     893,138       -       893,138  
Cash and cash equivalents at end of period   $ 18,550,437     $ -     $ 18,550,437